Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

We're sorry, but this trial is no longer enrolling volunteers.

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer


The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in subjects with HER2+ AR+ metastatic or locally advanced breast cancer.


Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.

Inclusion and Exclusion Criteria

  • - The subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+ - The subject has AR+ breast cancer - The subject has metastatic disease or has locally advanced disease that is not amendable to curative treatment - The subject has measurable disease or nonmeasurable, evaluable disease per RECIST
  • (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST 1.1). - The subject has received at least 1 line of therapy in the metastatic or locally advanced disease setting. The subject has been documented to have progressed by determination of the investigator on a regimen containing an anti-HER2 agent as the most recent regimen or the most recent anti-HER2 regimen was discontinued for any toxicity, with the exception of a cardiotoxicity. - The subject has adequately recovered from toxicities due to prior therapy. - The subject has an Eastern Cooperative Oncology Group performance (ECOG) status ≤ 1 at Screening and Day 1 - The subject has available at the site a representative, formalin-fixed, paraffin-embedded, tumor specimen that enabled the definitive diagnosis of breast cancer with adequate viable tumor cells in a tissue block (preferred) or ≥ 10 (20 preferred) freshly cut, unstained, serial slides and the associated pathology report

  • The subject has a severe concurrent disease, infection, or comorbidity that would make the subject inappropriate for enrollment.
  • The subject has current or previously treated brain metastasis or active leptomeningeal disease. Brain imaging is required during screening in all subjects to exclude the presence of unequivocal central nervous system disease.
  • The subject has a history of a non-breast cancer malignancy with the following exceptions:
  • The subject with a previous history of a non-invasive carcinoma is eligible if he/she has had successful curative treatment any time prior to Screening.
  • For all other malignancies, the subject is eligible if they have undergone potentially curative therapy and they have been considered disease free for at least 5 years prior to Screening.
  • The subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma).
  • The subject has a history of loss of consciousness, cerebrovascular accident, or transient ischemic attack within 12 months before the Day 1 visit.
  • The subject has had a hypoglycemic episode requiring medical intervention while on insulin (or other anti-diabetic) treatment within 12 months before Day 1.
  • The subject had a major surgical procedure, substantial open biopsy, or significant traumatic experience within 28 days before the Day 1 visit, or anticipation of need for major surgical procedure during the course of the study.
  • The subject has had palliative radiation therapy to bone metastases within 14 days prior to the Day 1 visit (side effects from radiation must be resolved).
  • The subject has received chemotherapy, immunotherapy, or any other systemic anticancer therapy, with the exception of anti-HER2 therapy (e.g., trastuzumab), within 14 days prior to the Day 1 visit.


  • California

    • USC Care Medical Group Inc., Los Angeles, California, 90033
    • Cedars-Sinai Medical Center, Los Angeles, California, 90048
    • East Valley Hematology Oncology Medical Group, Burbank, California, 91505
    • The Oncology Institute of Hope and Innovation, Whittier, California, 90603
    • Pacific Cancer Medical Center, Anaheim, California, 92801
  • Colorado

    • Univ of Colorado Cancer Center, Aurora, Colorado, 80045
  • Texas

    • The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104
  • Missouri

    • Washington University School of Medicine, Saint Louis, Missouri, 63110
  • Indiana

    • Indiana University School of Medicine, Indianapolis, Indiana, 46202
  • Ohio

    • Oncology Hematology Care, Cincinnati, Ohio, 45242
Powered by SC CTSI